EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo

Maryam Karimi, Arash Aslanabadi, Ben Atkinson, Mahsa Hojabri, Arshi Munawwar, Roza Zareidoodeji, Krishanu Ray, Parham Habibzadeh, Hanife Nur Karakoc Parlayan, Anthony DeVico, Alonso Heredia, Abdolrahim Abbasi und 1 weitere

Acta Biomaterialia · 2025-03 · 195 · 522-535

DOI: 10.1016/j.actbio.2025.02.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025-03. Verfasst von Maryam Karimi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Liposomes, Antibodies, Monoclonal, Drug Delivery Systems. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Monoclonal antibodies (mAbs) effectively treat and prevent various diseases, but their clinical application is hindered by issues related to the route of administration and pharmacokinetics (PK). Intravenous (IV) administration is cumbersome, while subcutaneous (SC) administration is hampered by lower bioavailability and potential for immunogenicity. This study evaluated the efficacy of liposomal formulations in enhancing the subcutaneous (SC) delivery and PK of broadly neutralizing antibodies (bNAbs) directed against HIV. METHODS: mAbs were encapsulated in liposomes with and without PEGylation. The liposomes were characterized for particle size, polydispersity index, zeta potential, and release. Thereafter, mice were injected with free mAbs or liposome-encapsulated mAbs, and PK was evaluated. RESULTS: Liposomes exhibited sizes of 85-92 nm with negative surface charges. Encapsulation efficiencies were 61 % for PEGylated and 58 % for non-PEGylated liposomes. Stability testing over 16 weeks revealed that formulations remained stable at 4 °C but showed leakage at 37 C. Cytotoxicity assays confirmed that the liposomal formulations did not affect cell viability or induce apoptosis in HMEC-1 cells. In vivo, PK studies in humanized FcRn mice indicated that the PEGylated formulations generally had higher half-life, Cmax, AUC, and MRT, and lower CL values compared to their non-PEGylated formulations of the same injection type. Both liposomal formulations showed improvements in bioavailability and extended half-life compared to free mAbs administered via SC and IV routes. Compared to the gold standard of IV free mAb injection, SC injection of antibodies encapsulated in PEGylated liposome had up to 80 % higher bioavailability and 45 % extension of half-life. Compared to the SC free mAb injection, the differences were even more pronounced, with liposomal SC injection having up to 113 % higher bioavailability and 81 % extension of half-life. CONCLUSION: Overall, liposomal encapsulation effectively protected SC injected mAbs from degradation, facilitated sustained release, and improved PK profiles, suggesting a promising strategy for enhancing the therapeutic potential of mAbs in conditions that need repeated injections. Future work should further optimize liposomal formulations to increase loading capacity, stability, and release kinetics. STATEMENT OF SIGNIFICANCE: This study addresses a challenge in the administration of monoclonal antibodies (mAbs). Intravenous administration requires additional resources, including nursing staff, making it time-consuming and costly. Although subcutaneous (SC) administration offers a less expensive and more patient-friendly option, it suffers from lower bioavailability and potentially shorter half-life. In this study, we encapsulated mAbs in liposomal formulations specifically designed to enhance their pharmacokinetics by promoting efficient lymphatic transport. Compared with both SC and even IV administration of free antibodies, liposomal formulations of mAbs remarkably improve bioavailability and extend the half-life. This innovative approach combines the comfort of SC administration with enhanced pharmacokinetics, addressing the limitations of current SC delivery methods. Liposomal formulations have the ability to greatly improve SC mAb administration by reducing the amount of antibody needed to be administered, reducing the frequency of injections, and potentially protecting against immunogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesAntibodies, MonoclonalDrug Delivery SystemsAnimalsHumansMiceInjections, SubcutaneousFemaleCell LinePolyethylene Glycols

Stichwörter der Autor:innen

Half-lifeLiposomeMonoclonal antibodies (mAbs)Pharmacokinetics (PK)Subcutaneous (SC) delivery

Substanzen

LiposomesAntibodies, MonoclonalPolyethylene Glycols

Autor:innen und Institutionen

  • Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Infectious Diseases, Karadeniz Technical University School of Medicine, Trabzon, Turkey.
  • Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: aabbasi@ihv.umaryland.edu.
  • Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: msajadi@ihv.umaryland.edu.

Förderung

  • Gates Foundation

Zitieren

APA

Karimi, M., Aslanabadi, A., Atkinson, B., Hojabri, M., Munawwar, A., Zareidoodeji, R., Ray, K., Habibzadeh, P., Parlayan, H. N. K., DeVico, A., Heredia, A., Abbasi, A., & Sajadi, M. M. (2025). Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo. Acta Biomaterialia, 195, 522-535. https://doi.org/10.1016/j.actbio.2025.02.035

Vancouver

Karimi M, Aslanabadi A, Atkinson B, Hojabri M, Munawwar A, Zareidoodeji R, et al. Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo. Acta Biomaterialia. 2025;195:522-535. doi:10.1016/j.actbio.2025.02.035

BibTeX
@article{Karimi2025,
  author = {Karimi, Maryam and Aslanabadi, Arash and Atkinson, Ben and Hojabri, Mahsa and Munawwar, Arshi and Zareidoodeji, Roza and Ray, Krishanu and Habibzadeh, Parham and Parlayan, Hanife Nur Karakoc and DeVico, Anthony and Heredia, Alonso and Abbasi, Abdolrahim and Sajadi, Mohammad M},
  title = {Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo},
  journal = {Acta Biomaterialia},
  year = {2025},
  volume = {195},
  pages = {522--535},
  doi = {10.1016/j.actbio.2025.02.035}
}
Kostenlos starten →